Research programme: musculoskeletal disorders therapies - Millenium Biologix Corporation

Drug Profile

Research programme: musculoskeletal disorders therapies - Millenium Biologix Corporation

Alternative Names: ACTES™-B implants - Millenium Biologix Corporation; ACTES™-C implants - Millenium Biologix Corporation

Latest Information Update: 02 Jun 2010

Price : $50

At a glance

  • Originator Millenium Biologix Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements; Intercellular signalling peptide and protein stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cartilage disorders; Musculoskeletal disorders

Most Recent Events

  • 06 Oct 2005 Early research in Cartilage disorders in Canada (Parenteral)
  • 06 Oct 2005 Early research in Musculoskeletal disorders in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top